Our analyses also identified resistance alterations that develop in the context of commonly used MM therapies, including iMiDs (CRBN and CUL4B), synthetic glucocorticoids (NR3C1), and monoclonal antibodies (CD38), which expands upon previous studies58,59. This evidence concerns the gene CD38 and Miyoshi myopathy.